120 related articles for article (PubMed ID: 2730043)
21. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of second cytoreductive surgery in the treatment of epithelial ovarian cancer.
Sun T; Feng Y
Chin Med J (Engl); 1998 Mar; 111(3):272-4. PubMed ID: 10374433
[TBL] [Abstract][Full Text] [Related]
23. [The effectiveness of platinum in mono- anc combination therapy in a prospective multicenter study].
Krafft W
Zentralbl Gynakol; 1989; 111(14):938-46. PubMed ID: 2678834
[TBL] [Abstract][Full Text] [Related]
24. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
25. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
Rufián S; Muñoz-Casares FC; Briceño J; Díaz CJ; Rubio MJ; Ortega R; Ciria R; Morillo M; Aranda E; Muntané J; Pera C
J Surg Oncol; 2006 Sep; 94(4):316-24. PubMed ID: 16917864
[TBL] [Abstract][Full Text] [Related]
26. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
Friedman RL; Eisenkop SM; Wang HJ
Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
[TBL] [Abstract][Full Text] [Related]
27. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
[TBL] [Abstract][Full Text] [Related]
28. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
29. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
30. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
31. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.
Littell RD; Hallonquist H; Matulonis U; Seiden MV; Berkowitz RS; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):570-4. PubMed ID: 16769104
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
33. [10 Year follow up of chemotherapy and surgery on the second laparotomy in advanced ovarian cancer].
Ojeda B; Llanos M; Brunet J; Lacasta A; Alonso MC; Rueda A; Delgado E; Badía J; López López JJ
Med Clin (Barc); 1995 Feb; 104(5):165-9. PubMed ID: 7877374
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the role of second-look surgery in ovarian cancer.
Chambers SK; Chambers JT; Kohorn EI; Lawrence R; Schwartz PE
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):404-8. PubMed ID: 3405557
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal cisplatin-based chemotherapy for primary treatment of epithelial ovarian cancer.
Del Prete SA; Ryan SP; Nelson JH
Conn Med; 2001 Feb; 65(2):71-5. PubMed ID: 11265604
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
40. The current therapeutic approaches to advanced ovarian cancer.
Nishimura H; Hamaguchi K; Miyahara K; Tazaki T; Tateno N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1691-6. PubMed ID: 2277209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
